NO119588B - - Google Patents
Download PDFInfo
- Publication number
- NO119588B NO119588B NO159321A NO15932165A NO119588B NO 119588 B NO119588 B NO 119588B NO 159321 A NO159321 A NO 159321A NO 15932165 A NO15932165 A NO 15932165A NO 119588 B NO119588 B NO 119588B
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- benzodiazepine
- dihydro
- acid
- chloro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 claims description 3
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229910003446 platinum oxide Inorganic materials 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 ketone radical Chemical class 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Fremgangsmåte for fremstilling av terapeutisk aktive benzodiazepin-derivater.
Nærværende oppfinnelse vedrorer en fremgangsmåte for fremstill-
ing av terapeutisk aktive benzodiazepin-derivater med den generelle formel
hvor betyr halogen, R2fenyl eller pyridyl og R^metyl eller fenyl og syreaddisjonssalter av disse forbindelser. i Fremgangsmåten ifolge oppfinnelsen karakteriseres ved at man reduserer carbonylgruppen i sidekjeden i 1-stilling i en forbindelse med den generelle formel
hvor R-p R2og R^har foran angitte betydning.
Reduksjonen av ketonradikalet i 1-stilling i forbindelsen ifolge formel II kan finne sted ved katalytisk hydrering f.eks. hydrering i nærvær av platinoxyd eller ved behandling av forbindelsen med formel II med et borhydrid eller et eller annet , egnet reduksjonsmiddel, som fortrinnsvis selektivt bevirker reduksjonen av carbonylgruppen i 1-stilling. De foretrukne i reagenser er alkaliborhydrider, f.eks. lithiumborhydrid, kal-! iumborhydrid og i særdeleshet natriumborhydrid. Andre bor- hydrider, som jordalkalborhydrider, f.eks. kalsiumborhydrid eller aluminiumborhydrid kan likeledes nevnes. Fortrinnsvis
benyttes ved anvendelse av borhydrid som reaksjonsmedium et organisk opplosningsmiddel, som ether, f.eks. dietyllether,
tetrahydrofuran, eller en lavere alkanol, f.eks. methanol, ethanol eller propanol. Reduksjonen kan gjennomfores såvel ved værelsetemperatur som også ved forhoyet temperatur og,
hvis nodvendig, under inert-gassatmosfære, f.eks. under nitro-gen.
Forbindelser med formel I danner syreaddisjonssalter med u-organiske og organiske syrer, f.eks. halogenhydrogensyrer, som saltsyre og bromhydrogensyre, svovelsyre, fosforsyre, salpeter-syre, vinsyre, sitronsyre, kamfersulfonsyre, ethansulfonsyre, ascorbinssyre, salicylsyre, maleinsyre og lignende.
Forbindelser med formel I og deres farmasoytisk anvendbare syreaddisjonssalter innehar muskelrelakserende, sedative og
antikonvulsive egenskaper. De kan innvendig administreres f. eks. parenteralt eller enteralt i vanlig farmasoytisk form. F.eks. kan de innarbeides i vanlige flytende eller faste bære-stoffer, som vann, gelatin, stivelse, magnesiumstearat, talkum, vegetabilske oljer og lignende under dannelse av tabletter,
kapsler, oppløsninger, emulsjoner tilsvarende den generelle vanlige farmasøytiske teknikk.
De følgende eksempler anskueliggjør fremgangsmåten ifolge oppfinnelsen; alle temperaturene<r>er angitt i Celsiusgrader.
Eksempel 1
Til 12,0 g (30,8 mmol) 7-klor-l,3-dihydro-l-fenacyl-5-fenyl-2H-l,<1>+-benzodiazepin-2-on i 200 ml ethanol tilsetter man i små porsjoner i lopet av 1 time omhyggelig 1,20 g (33 mmol) natriumborhydrid. Reaksjonsblandingen rores natten over og konsentreres så i vakuum. Konsentratet helles i vann. Det erholdte vandige medium innstilles basisk med fortynnet natronlut!og ekstraheres med methylenklorid. Man oppnår 7-klor-l,3- dihydro-l-(p-hydroxy-fenetyll)-5-fenyl-2H-l,<L>F-benzodiazepin-2-on som svakt gul-farvet, gummilignende produkt.
Den frie "base opploses i et lett overskudd over den beregnede mengde methanolisk l-n saltsyre. Etter tilsetning av ether skiller 7-klor-l ,3-dihydro-1-((3-hydroxy-f ene tyll)-5-fenyl-2H-1 ,if-benzodiazepin-2-on-hydrokloridet seg ut. Etter omkrystallisasjon fra methanol-aceton danner forbindelsen farvelose nåler med smp. -216-217°.
Det som utgangsmaterial anvendte 7-klor-l,3-dihydro-l-fenacyl-5-fenyl-2H-l,i+-benzodiazepin-2-on kan fremstilles på folgende måte: 0,100 mol 7-klor-l,3-dihydro-5-fenyl-2H-lj^—benzodiazepin-2-on opploses i 200 ml vannfri dimetyllformamid. Forbindelsen over-fores ved tilsetning av .0,110 mol natriummethoxyd til natrium-salt. Man rbrer reaksjonsblandingen og oppvarmer i 15 minutter under beskyttelse for atmosfærisk fuktighet på damp-bad. Deretter loser man 0,110 mol fenacylbromid i 165 nil toluol og tilsetter den erholdte opplosning i lopet av 30-^5 minutter til den oppvarmete reaksjonsblanding. Etter fullstendig tilsetning oppvarmer og rorer man ytterligere 2 timer. Reaksjonsblandingen konsentreres så i vakuum til et lite volum og helles langsomt i et stort volum isvann. Det danner seg et bunnfall, som filtreres fra. Ved omkrystallisasjon av bunnfallet fra ethanol oppnår man 7-klor-l,3-dihydro-l-fenacyl-5-fenyl-2H-l,Li--benzodiazepin-2-on i form av farvelose prismer med smp. 17*4-175°.
Eksempel 2
Til en opplosning av 20,0 g (61 mmol) l-acetonyl-7-klor-l,3-dihydro-5-fenyl-2H-l,<1>+-benzodiazepin-2-on i 250 ml ethanol tilsetter man i små porsjoner i lopet av 1 time omhyggelig 2,55 g ....
(68 mmol) natriumborhydrid. Reaksjonsblandingen rores natten over og konsentreres så i vakuum. Det erholdte konsentrat helles i vann, innstilles alkalisk med fortynnet natronlut og
ekstraheres med methylenklorid. Man oppnår 7-klor-l,3-dihydro-1- ((3-hydroxy-propyl)-5-fenyl-2H-l ,if-benzodiazepin-2-on som gult, gummi-lignende produkt.
Den frie base opploses i et lett overskudd over den beregnede mengde l-n saltsyre. Etter tilsetning av ether skiller 7-klor-1,3-dihydro-l- ((3-hydroxy-propyl) - J-f enyl-2H-l ,^-benzodiazepin-2- on-hydrokloridet seg ut. Etter omkrystallisasjon fra methan-ol/aceton/ether oppnår man hydrokloridet i form av gule prismer med smp. 203-205°.
Det som utgangsmaterial anvendte l-acetonyl-7-klor-l,3-dihydro-5-fenyl-2H-l,<1>+-benzodiazepin-2-on kan fremstilles på folgende måte:
0,100 mol 7-klor-l,3-dihydro-5-fenyl-2H-l,lf-benzodiazepin-2-
on opploses i 200 ml vannfri dimetyllformamid. Man omvandler forbindelsen ved tilsetning av 0,110 mol natriummethoxyd til natriumsaltet. Reaksjonsblandingen rores og oppvarmes 15 minutter under beskyttelse for atmosfærisk fuktighet på et dampbad. Man loser 0,110 mol 1-kloraceton i 165 ml toluol og tilsetter den erholdte opplosning i lopet av 30-^5 minutter omhyggelig til en oppvarmet reaksjonsblanding. Etter full-
stendig tilsetning rores og oppvarmes reaksjonsblandingen ytterligere 2 timer. Reaksjonsblandingen konsentreres så i vakuum til et lite volum og helles langsomt i et stort volum isvann. Det danner seg et bunnfall, som filtreres fra. Ved omkrystallisasjon av bunnfallet fra aceton, oppnår man 1-acetonyl-7-klor-l ,3-dihydro-5-f enyl-2H-l ,1+-benzodiazepin-2-on i form av farvelose prismer, smp. 169-171°•
Eksempel
En opplosning av 5)25 g (l<*>fmmol) l-acetonyl-7-brom-l ^-di-hydro^-^-pyridyl)-2H-1 ^-benzodiazepin^-on i 80 ml ethanol rores ved værelsetemperatur. Til den rorte opplosning tilset-
ter man omhyggelig 0,59 g (15A mmol) natriumborhydrid. Den erholdte opplosning rores 16 timer ved 25°?konsentreres i
vakuum og fortynnes med 300 ml isvann. Man tilsetter i overskudd (ca. 5 ml) 3-n natronlut og ekstraherer reaksjonsblandingen med methylenklorid. Ekstraktet vaskes med vann, torkes over vannfritt natriumsulfat og inndampes. Den erholdte gule rest opploses i benzol og renses ved filtrering over en kolonne som inneholder noytral aluminiumoxyd (aktivitetsgrad III).
Man eluerer med benzol og med blanding av benzol og methylenklorid og inndamper eluatene. Man oppnår 7-brom-l,3-dihydro-1- ((3-hydroxy-propyl) -5- (2-pyridyl) -2H-1 ,L)--benzodiazepin-2-on. Reaksjonsproduktet omkrystalliseres fra ether/petrolether og danner farvelose nåler med smp. 126-128°.
Det som utgangsmaterial anvendte l-acetonyl-7-brom-l,3-dihydro-5-(2-pyridyl)-2H-1,<1>+-benzodiazepin-2-on kan fremstilles på folgende måte: Til en opplosning av 10 g (31,8 mmol) 7-brom-l,3-dihydro-5-(2-pyridyl)-2H-1 ,lf-benzodiazepin-2-on i 150 ml vannfri N,N-dimetyllformamid tilsetter man 1,85 g (35 mmol) natriummethoxyd. Reaksjonsblandingen rores<*>f timer ved værelsetemperatur. Man tilsetter en liten mengde (ca. 50-100 mg) fin-pulverisert natriumjodid og tilsetter deretter dråpevis en opplosning av 2,9 ml (3,3 g, 35 mmol) kloraceton i 20 ml vannfri dimetyllformamid i lopet av 30 minutter. Reaksjonsblandingen rores 20 timer ved 25° og deretter h timer ved . Man heller i 1,7 1 isvann og ekstraherer med methylenklorid. Det torre ekstrakt renses ved filtrering gjennom en kolonne,som inneholder 50 g noytralt aluminiumoxyd (aktivitetsgrad III). Etter fordampning av eluatet oppnår man l-acetonyl-7-brom-l,3-dihydro-5-(2-pyridyl)-2H-1,V-benzodiazepin-2-on i form av et svakt gult, gummi-lignende produkt, hvilket renses ved ekstraksjon med blandinger av benzol og hexan. Ved fordampning av ekstraktet oppnår man et svakt gul-farvet gummilignende produkt, hvilket omkrystalliseres fra methylenklorid/hexan og gir så farvelose prismer med smp. 156-158°.
Claims (1)
- Fremgangsmåte for fremstilling av terapeutisk aktive benzodi- azepinderivater med den generelle formeli i hvor betyr halogen, R^fenyl eller pyridyl og R^metyl eller fenyl og syreaddisjonssalter av disse,karakterisert vedat carbonylgruppen i sidekjeden i 1-still-j ing i en forbindelse med den generelle formel iI" hvor R^, R2og R^ har foran angitte betydning, reduseres, i fortrinnsvis med hydrogen i nærvær av platinaoxyd eller med I et borhydrid,og overforer/hvis onsket det erholdte reaksjons-produkt til et syreaddisjonssalt.' 1 I 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38946964A | 1964-08-13 | 1964-08-13 | |
US474159A US3391138A (en) | 1964-08-13 | 1965-07-22 | Certain 1-substituted-benzodiazepin-2-one compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO119588B true NO119588B (no) | 1970-06-08 |
Family
ID=27012718
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO159321A NO119588B (no) | 1964-08-13 | 1965-08-12 | |
NO159320A NO118914B (no) | 1964-08-13 | 1965-08-12 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO159320A NO118914B (no) | 1964-08-13 | 1965-08-12 |
Country Status (12)
Country | Link |
---|---|
US (1) | US3391138A (no) |
BE (2) | BE668188A (no) |
BR (2) | BR6571653D0 (no) |
CH (1) | CH462831A (no) |
DE (2) | DE1545952C3 (no) |
DK (2) | DK125554B (no) |
FR (1) | FR135F (no) |
GB (2) | GB1102934A (no) |
IL (2) | IL23998A (no) |
NL (2) | NL6510538A (no) |
NO (2) | NO119588B (no) |
SE (2) | SE312558B (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL33961A (en) * | 1969-03-13 | 1973-03-30 | Sparamedica Ag | Benzodiazepine aminoalkyl carboxylates,their preparation and pharmaceutical compositions containing them |
US3989829A (en) * | 1969-04-18 | 1976-11-02 | Sumitomo Chemical Company, Limited | 1,4-Benzodiazepines |
USRE28972E (en) * | 1969-07-10 | 1976-09-21 | Boehringer Ingelheim Gmbh | 5-Aryl-1H-1,5-benzodiazepine-2,4-diones |
US3867372A (en) * | 1970-02-03 | 1975-02-18 | Sumitomo Chemical Co | Benzodiazepine process |
US3691157A (en) * | 1970-08-12 | 1972-09-12 | Rodney Ian Fryer | Preparation of 7-substituted-1-(2-diethylaminoethyl)-5-(2-halophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-ones |
US3910889A (en) * | 1970-08-31 | 1975-10-07 | Sumitomo Chemical Co | Novel benzodiazepine derivatives and preparation thereof |
AT314541B (de) * | 1970-10-19 | 1974-04-10 | Sumitomo Chemical Co | Verfahren zur Herstellung von neuen Benzodiazepinen und ihren Salzen |
US3886276A (en) * | 1971-03-30 | 1975-05-27 | American Home Prod | 1,3-Dihydro-3 -hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one, substituted diamino acetate esters and their acid salts in compositions and methods for inducing a calming effect |
US4065451A (en) * | 1971-03-30 | 1977-12-27 | American Home Products | 1,3-Dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one, substituted diamino acetate esters and their acid salts |
US3872089A (en) * | 1971-05-14 | 1975-03-18 | Hoffmann La Roche | Substituted thienodiazepines |
US3966943A (en) * | 1971-09-13 | 1976-06-29 | The Upjohn Company | 6-Pyridyl benzodiazepines antidepressants |
US3926952A (en) * | 1972-10-03 | 1975-12-16 | American Home Prod | 1,4-Benzodiazepin-2-ones and their synthesis |
US4012413A (en) * | 1973-05-17 | 1977-03-15 | The Upjohn Company | Organic compounds and process |
US3865815A (en) * | 1973-11-29 | 1975-02-11 | Hoffmann La Roche | 7-Hydroxyamino-1,4-benzodiazepines |
US4006135A (en) * | 1974-06-19 | 1977-02-01 | Ddsa Pharmaceuticals | Hydroxymethyl benzodiazepine derivatives |
US3969504A (en) * | 1975-02-14 | 1976-07-13 | The Upjohn Co. | 6-Phenyl benzodiazepine antidepressants |
DE2852606A1 (de) * | 1977-12-14 | 1979-06-21 | Gerot Pharmazeutika | 3-di-n-propyl-acetoxy-benzodiazepin-2-one und verfahren zu deren herstellung |
AT361492B (de) * | 1978-12-18 | 1981-03-10 | Gerot Pharmazeutika | Verfahren zur herstellung von neuen 3-hydroxy- 1,4-benzodiazepin-2-onen |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3236838A (en) * | 1964-06-09 | 1966-02-22 | Hoffmann La Roche | Certain 1-substituted-benzodiazepin-2-one compounds |
-
0
- FR FR135D patent/FR135F/fr active Active
-
1965
- 1965-07-21 IL IL23998A patent/IL23998A/xx unknown
- 1965-07-21 IL IL23999A patent/IL23999A/en unknown
- 1965-07-22 US US474159A patent/US3391138A/en not_active Expired - Lifetime
- 1965-07-23 CH CH1036865A patent/CH462831A/de unknown
- 1965-07-27 DE DE1545952A patent/DE1545952C3/de not_active Expired
- 1965-07-29 DE DE19651545953 patent/DE1545953A1/de active Pending
- 1965-07-29 BR BR171653/65A patent/BR6571653D0/pt unknown
- 1965-07-29 BR BR171654/65A patent/BR6571654D0/pt unknown
- 1965-08-09 GB GB33994/65A patent/GB1102934A/en not_active Expired
- 1965-08-09 GB GB44504/67A patent/GB1106040A/en not_active Expired
- 1965-08-11 DK DK411365AA patent/DK125554B/da unknown
- 1965-08-11 DK DK411265AA patent/DK120848B/da unknown
- 1965-08-12 NL NL6510538A patent/NL6510538A/xx unknown
- 1965-08-12 BE BE668188D patent/BE668188A/xx unknown
- 1965-08-12 BE BE668189D patent/BE668189A/xx unknown
- 1965-08-12 NO NO159321A patent/NO119588B/no unknown
- 1965-08-12 NO NO159320A patent/NO118914B/no unknown
- 1965-08-12 NL NL6510539A patent/NL6510539A/xx unknown
- 1965-08-13 SE SE10629/65A patent/SE312558B/xx unknown
- 1965-08-13 SE SE10628/65A patent/SE310687B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SE312558B (no) | 1969-07-21 |
DE1545952A1 (de) | 1969-12-18 |
CH462831A (de) | 1968-09-30 |
IL23998A (en) | 1969-02-27 |
GB1106040A (en) | 1968-03-13 |
DK125554B (da) | 1973-03-05 |
BE668188A (no) | 1966-02-14 |
SE310687B (no) | 1969-05-12 |
NO118914B (no) | 1970-03-02 |
DK120848B (da) | 1971-07-26 |
NL6510539A (no) | 1966-02-14 |
DE1545952B2 (de) | 1974-07-04 |
DE1545953A1 (de) | 1969-11-20 |
US3391138A (en) | 1968-07-02 |
BR6571653D0 (pt) | 1973-08-14 |
FR135F (no) | |
BE668189A (no) | 1965-12-01 |
DE1545952C3 (de) | 1975-03-06 |
IL23999A (en) | 1969-05-28 |
NL6510538A (no) | 1966-02-14 |
BR6571654D0 (pt) | 1973-08-14 |
GB1102934A (en) | 1968-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO119588B (no) | ||
EP0328026B1 (de) | Substituierte Pyrrole | |
Anderson et al. | Synthesis and antileukemic activity of 5-substituted 2, 3-dihydro-6, 7-bis (hydroxymethyl)-1H-pyrrolizine diesters | |
DE1695093A1 (de) | Neue Imidazolderivate | |
IL22869A (en) | A benzodiazepine derivative and process for the manufacture thereof | |
EP1861390A1 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
NO154116B (no) | Fremgangsm¨te og lamellsepareringsapparat for tilf¯rsel og fordeling av en sammensatt v|ske til et lamellseparerings apparat. | |
US3538104A (en) | Pyridyl-2-imidazolones | |
US5102891A (en) | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates | |
NO801843L (no) | Nye kinazolinderivater og farmasoeytiske preparater | |
DE1695943A1 (de) | Verfahren zur Herstellung von neuen 1,2,3,4,5,6-Hexahydroazepino(4,5-b)indolen und deren Saeureanlagerungssalzen | |
Robison et al. | The Rearrangement of Isoquinoline-N-Oxides. II. Observations with N-Hydroxyisocarbostyrils and Other Substituted Derivatives1 | |
US2987518A (en) | Certain 1h [4, 5-c]-imidazopyridines | |
NO118975B (no) | ||
DE2030315A1 (no) | ||
IL24659A (en) | Process for the manufacture of benzodiazepine derivatives and new benzodiazepine derivatives | |
Manske et al. | THE ALKALOIDS OF FUMARIACEOUS PLANTS: XVII. CORYDALIS CASEANA A. GRAY | |
NO165419B (no) | Innretning for laasing og frigjoering av gjenstander beregnet for offentlig bruk, saasom bagasjetraller. | |
AT256115B (de) | Verfahren zur Herstellung von neuen Benzodiazepin-Derivaten | |
JPH0753730B2 (ja) | イミダゾピラゾール誘導体 | |
Dannley et al. | THE CONDENSATION OF PHOSPHONOTHIOIC AND PHOSPHONIC DICHLORIDES WITH o-DIAMINES | |
IL29772A (en) | Benzodiazepine derivatives and process for the manufacture thereof | |
Becker et al. | Structure of the Hemihydrates of Phenylglyoxals1, 2 | |
NO123037B (no) | ||
NO126739B (no) |